Understanding platinum-induced ototoxicity

Langer, Thorsten; Zehnhoff‐Dinnesen, Antoinette am; Radtke, Susanne; Meitert, Johannes; Zolk, Oliver

doi:10.1016/j.tips.2013.05.006

Cited by 196 publications

(180 citation statements)

References 51 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…Age-related hearing loss, noise-induced hearing loss, and ototoxicity has been shown to occur as a result of an apoptotic process [3][4][5][6][7] . KRG extracts, or its specific saponins, were shown to have antiapoptotic and antioxidant properties in various tissues both in vitro and in vivo [8] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protective Effect of Korean Red Ginseng on Cisplatin Ototoxicity: Is It Effective Enough?

Olgun¹,

Kırkım²,

Altun³

et al. 2016

Int Adv Otol

View full text Add to dashboard Cite

1 (HEI-OC1) cell line. Cells were treated with CDDP, KRG, and their combination for 24 h. Cell viability, apoptosis, and the expression of 84 apoptosis-related genes were analyzed. In the second part of the study, 30 Wistar albino rats were divided into five groups. Baseline distortion product otoacoustic emissions (DPOAEs) and auditory brainstem response (ABR) measurements were obtained. In groups I, II, and III, only saline, KRG, and CDDP, respectively, were given. In group IV, 500 mg/kg KRG and in group V, 150 mg/kg of KRG were administered for 10 days. In groups III, IV, and V, 16 mg/kg CDDP injections were administered on day 11. On day 14, final DPOAEs and ABR measurements were completed. The rats were then sacrificed, and their inner ear structures were evaluated by transmission electron microscopy. RESULTS:In the first part of the study, pretreatment with 1 mg/mL KRG protected cells from CDDP ototoxicity. This protection was mainly due to a decline in apoptotic gene expression and an increase in antiapoptotic gene expression. In the in vivo part of the study, we found that both KRG doses had otoprotective effects. This protection was more prominent at the lower dose, especially on the spiral ganglion and the brainstem.CONCLUSION: KRG was shown to be an otoprotective agent against CDDP-induced ototoxicity both in vivo and in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Ototoxicity could lead to language and speech disabilities in young children [1][2] . The mechanism of CDDP-induced ototoxicity is apoptosis, and outer hair cells, stria vascularis, and spiral ganglion neurons are mainly affected [3][4][5][6][7] .…”

Section: Introductionmentioning

confidence: 99%

Protective Effect of Korean Red Ginseng on Cisplatin Ototoxicity: Is It Effective Enough?

Olgun¹,

Kırkım²,

Altun³

et al. 2016

Int Adv Otol

View full text Add to dashboard Cite

show abstract

“…Hearing loss is detectable in 20%-60% of childhood cancer survivors who received platinum-based treatment (Hudson et al, 2013). It has educational, vocational, and social consequences that may vary by age of onset (Bertolini et al, 2004;Brock et al, 2012;Langer, am Zehnhoff-Dinnesen, Radtke, Meitert, & Zolk, 2013;Travis et al, 2014). Tinnitus, which may interfere with sleep, daily function, and quality of life (Sprauten et al, 2012), is another important hearing outcome that is common following platinum chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Patient-Reported Measures of Hearing Loss and Tinnitus in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review

Stark

Rosenberg

Johnston

et al. 2016

J Speech Lang Hear Res

View full text Add to dashboard Cite

Purpose We identified studies that described use of any patient-reported outcome scale for hearing loss or tinnitus among children and adolescents and young adults (AYAs) with cancer or hematopoietic stem cell transplantation (HSCT) recipients. Method In this systematic review, we performed electronic searches of OvidSP MEDLINE, EMBASE, and PsycINFO to August 2015. We included studies if they used any patient-reported scale of hearing loss or tinnitus among children and AYAs with cancer or HSCT recipients. Only English language publications were included. Two reviewers identified studies and abstracted data. Results There were 953 studies screened; 6 met eligibility criteria. All studies administered hearing patient-reported outcomes only once, after therapy completion. None of the studies described the psychometric properties of the hearing-specific component. Three instruments (among 6 studies) were used: Health Utilities Index (Barr et al., 2000; Fu et al., 2006; Kennedy et al., 2014), Hearing Measurement Scales (Einar-Jon et al., 2011; Einarsson et al., 2011), and the Tinnitus Questionnaire for Auditory Brainstem Implant (Soussi & Otto, 1994). All had limitations, precluding routine use for hearing assessment in this population. Conclusions We identified few studies that included hearing patient-reported measures for children and AYA cancer and HSCT patients. None are ideal to take forward into future studies. Future work should focus on the creation of a new psychometrically sound instrument for hearing outcomes in this population.

show abstract

“…These include cumulative cisplatin dose and dosing schedule, patient age at treatment, pre-existing hearing impairment, concomitant use of aminoglycosides and cranial irradiation (Box 1) 21 . It is now recognized that there is significant variability in hearing loss between individual patients receiving similar cumulative doses and application schedules of cisplatin suggesting that clinical risk factors alone are insufficient predictors of safety 15 .…”

Section: Risk Factors For Cisplatin-induced Ototoxicitymentioning

confidence: 99%

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Lee

Pussegoda

Rassekh

et al. 2016

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Abstract:Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field; (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment and management of cisplatin-induced hearing loss in children and adults; and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin based chemotherapy.

show abstract

Understanding platinum-induced ototoxicity

Cited by 196 publications

References 51 publications

Protective Effect of Korean Red Ginseng on Cisplatin Ototoxicity: Is It Effective Enough?

Protective Effect of Korean Red Ginseng on Cisplatin Ototoxicity: Is It Effective Enough?

Patient-Reported Measures of Hearing Loss and Tinnitus in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Contact Info

Product

Resources

About